Stereotaxis to Report First Quarter 2026 Financial Results on May 12, 2026
Rhea-AI Summary
Stereotaxis (NYSE: STXS) will report its first quarter 2026 financial results after U.S. market close on Tuesday, May 12, 2026. The company will host a live conference call and webcast at 4:30 p.m. ET to discuss results and corporate developments.
Dial-in numbers and a live/replay webcast will be available via the company’s investor relations website; a phone replay will be accessible for one month beginning about four hours after the call.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – STXS
On the day this news was published, STXS declined 3.03%, reflecting a moderate negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $6M from the company's valuation, bringing the market cap to $187.16M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
STXS was down 2.46% while close peers showed mixed moves: OSUR +0.95%, MBOT +0.44%, INFU +3.85%, STSS -1.08%, NYXH -0.62%, suggesting stock-specific trading rather than a unified sector move.
Previous Earnings date Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 12 | Earnings date announcement | Neutral | -0.5% | Set reporting date and call details for Q4 and full-year 2025 results. |
Prior earnings-date scheduling produced a small negative move, suggesting limited standalone impact from such announcements.
Over the last several months, Stereotaxis reported strong 2025 growth, secured FDA clearance and launch of the Synchrony system, expanded its installed base with new robotic programs, and announced a definitive agreement to acquire Robocath. Against this backdrop, the company has also followed a consistent practice of pre-announcing earnings dates, as on Feb 12, 2026. Today’s first-quarter 2026 earnings-date notice fits that communication pattern amid ongoing operational and strategic developments.
Historical Comparison
In the past 6 months, STXS had 1 prior earnings-date announcement with an average move of -0.49%, indicating historically modest reactions to scheduling news alone.
Earnings communications have followed a pattern of pre-announcing call logistics ahead of detailed financial releases.
Regulatory & Risk Context
An effective S-3 shelf filed on 2026-03-13 allows Stereotaxis to issue up to $100,000,000 of securities, including an at-the-market program previously sized at $50,000,000, with $42,139,304 from the prior sales agreement included under this registration.
Market Pulse Summary
This announcement sets the date and time for first quarter 2026 results and provides access details for the call and webcast. It does not introduce new financial figures but sits within a period of active regulatory filings, product launches, and an announced acquisition. Investors may focus on how upcoming results compare with prior guidance and recent growth trends, while also monitoring the company’s capital-raising flexibility under its $100,000,000 shelf registration.
Key Terms
surgical robotics medical
minimally invasive endovascular intervention medical
AI-generated analysis. Not financial advice.
ST. LOUIS, April 21, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2026 first quarter on Tuesday, May 12, 2026 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. EST that day to discuss the Company’s results and corporate developments.
| What: | Stereotaxis first quarter 2026 financial results conference call | |
| When: | Tuesday, May 12, 2026, at 4:30 p.m. ET (1:30 p.m. PT) | |
| Dial In Number: | To access the live call, dial 800-715-9871 (US and Canada) or 1-646-307-1963 (International) and give the participant pass code 6082771. | |
| Webcast: | To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at http://ir.stereotaxis.com/. | |
| Call Replay: | A phone replay of the call will be available for one month beginning approximately four hours following the end of the call. To request access for a replay of the conference call, please click here. | |
About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com.
Investor Contacts:
David L. Fischel
Chairman and Chief Executive Officer
Kimberly Peery
Chief Financial Officer
314-678-6100
Investors@Stereotaxis.com
